Initiation of Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites View press release.

They Call it The Miracle
What if a novel psychedelic could be the solution to one of society's most complicated and expensive mental health issues: Alcohol Use Disorder?
Our First Indication
Alcohol Use Disorder
Over 57 million Americans report four or more episodes of heavy drinking per month...
... With an average of seven drinks per episode.1

Over 18 million Americans struggle with Alcohol Use Disorder2—the inability to reduce alcohol consumption

55% of victims of intimate partner violence report alcohol abuse by their abusive partner.3

Approximately half of all sexual assaults are committed by men who had been drinking alcohol.4

35% of parental child abuse offenders consumed either alcohol or drugs at the time of the incident.5
The Economic Cost
Alcohol and substance abuse have a higher economic burden than heart disease, depression and other leading health problems.


$193 billion3
Substance Abuse
$249 billion2
Alcohol Abuse
[1] US DOJ 2011, Bouchery, Horwood, Sacks, Simon & Brewer, 2011; Mrazek, Hornberger, Altar, & Degliar, 2014.
[2] Sacks, J. J., Gonzales, K. R., Bouchery, E. E., Tomedi, L. E., & Brewer,R. D. (2015). 2010 national and state costs of excessive alcohol consumption. American Journal of Preventive Medicine, 49(5), e73-e79. The Competition
Large Market & Competitive Density
Our Solution
MEAI: A New Psychoactive Molecule

5-Methoxy-2-aminoindane, or "MEAI"
MEAI exerts a euphoric alcohol-like experience and a reduced desire to consume alcoholic beverages with potential to change the lives of millions who struggle to drink in moderation.
How MEAI Works
Mark Haden, Clearmind’s VP Business Development, describes the MEAI treatment experience.
Why MEAI is Different
A New and Unique Psychedelic Treatment
Our Patents
A Portfolio of 19 Patent Families


Clearmind patents consist of 19 utility patent families owned by the company.

These include 31 granted patents.
Our Treatments
Proprietary Treatment Candidates
Our Team
An experienced public company leader and a skilled navigator of clinical trial processes, Dr. Zuloff-Shani is leading the Clearmind team.

Adi Zuloff-Shani, PhD
Dr. Adi Zuloff-Shani is a Biomedical Research and Development Executive with a vast experience with over 20 years of strategic and operational leadership in the healthcare industry and a deep understanding of therapeutics development in heavily regulated environments.
View TeamJoin Us
Let's Make History